🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“As a woman and a female scientist, I told my fellows; you can have both (a family and a career). You don’t need to over-assist your child. Your child will watch you and and they will do!”

We think these recommendations will generate ideas for the next generation of #RectalCancer clinical trials. I appreciate leading this work with Prajnan Das, MD, MS, MPH, @NCICTEP_ClinRes Dr. Cathy Eng Karyn Goodman, MD, MS !

🎯Raludotatug deruxtecan R-DXd (CDH6 #AntibodyDrugCongugate) yields objective response rate of 46% and disease control rate of 98% in platinum resistant #OvarianCancer despite a median prior therapies of 4!! #ESMO2023 #gyncsm

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM nejm.org/doi/full/10.10… Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.

Congrats Justin Moyers!!!🎉🎊 This is such an accomplishment within 6 months of arrival Angles Clinic!!!

We use a novel 2-mo RECIST organ-specific response assessment to dissect the impact of IO on responses in different sites of MSS MCRC. Check the article to learn more on how sites of metastases impact response. Liver, lung, peritoneum, and others- ejcancer.com/article/S0959-…

I couldn’t be more proud of my fav partner-in-crime, amazing clinician and scientist, the best writer and human being…Jun Gong. Nature for 5 yrs in and NEJM next! nature.com/articles/s4158…

Liver Metastases & Immune Checkpoint Inhibitor Efficacy in Refractory mCRC JAMA Network Open doi.org/10.1001/jamane… 🔎CCTG CO.26 trial 👉Pts without LM have significantly improved DCR, PFS & OS with Durva/Treme vs BSC 🧐consistent finding, important for future trial design

Yet another clinical trial failure by applying “targeted” therapy in an un-targeted fashion. While some cancer type have germ-line mutations (e.g., BRCA) which allow broader use of this drug class, NSCLC is not one of them. Even when BRCA-mutated, in NSCLC most are mono-allelic

In MSI high mCRC Ipi Nivo was dramatically superior to chemo first line with marked improved PFS. Results of Nivo alone awaited. Establishes a new first line option in MSI high mCRC.

A new study from Michael Cecchini and colleagues at Yale Cancer Center found olaparib and ramucirumab is well-tolerated with efficacy for metastatic #gastriccancer and #GEJadenocarcinoma. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp nature.com/articles/s4141…

Congrats Michael Cecchini! You have incubated this project since fellowship!

Only Jun Gong can do this! Has been writing/publishing dual/triple since fellowship City of Hope Department of Medical Oncology with Dr. Marwan G. Fakih and Sumanta K. Pal, MD, FASCO!

💊Adding durvalumab plus bevacizumab to TACE in unresectable HCC EMERALD-1, ASCO GI24 Journal of Clinical Oncology ✅D+B+TACE vs TACE mPFS: 15.0 vs 8.2 mo, HR: 0.77 (0.61–0.98) p=0.032 ❌D+TACE vs TACE mPFS: 10.0 vs 8.2 mo, HR: 0.94 (0.75–1.19) p=0.638 👉ascopubs.org/doi/10.1200/JC… ⁉️Whether it

Universe listens to your inner voice. Been wanting to meet this inspiring Dr Joseph McCollom DO and got a chance to have “peer mentoring” session and learned how he’s improving much needed pall care for GI Onc pts since the first day of their journeys!

Who would not love working with Hagen Kennecke!!!

From @asco as led by: Aaron J. Scott MD @sepidah_gholami Myriam Chalabi Hagen Kennecke May Cho Manju George MVSc PhD Rectal Cancer Survivor Josh Smith, MD, PhD, FACS : Management of Locally Advanced Rectal Cancer: ASCO Guideline pubmed.ncbi.nlm.nih.gov/39116386/ #crcsm #rectalcancer #cancer #CancerResearch OncoAlert

I will be riding in my 6th closer to free bike ride on 9/7/2024. The ride is a great experience to join the Yale Cancer Center community and support cancer research. Please support my ride at the following link: rideclosertofree.org/participant/31… My goal is to raise at least $500!

Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite … pubmed.ncbi.nlm.nih.gov/39256132/ Our single center experience as summarized by our super Fellow Dr. Annie Xioa supports early discontinuation in settings of Clinical CR.

ctDNA-based MRD & survival in resectable CRC Nature Medicine doi.org/10.1038/s41591… 🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts 👉shorter DFS in MRD+ patients 👉Better outcome after sustained ctDNA clearance in response to ACT 🧐What else do we need to implement into clinical practice?